TY  - CONF

T1  - Adjuvant bevacizumab as treatment for melanoma patients at high risk of recurrence: Final results for the AVAST-M trial.

JO  - Journal of Clinical Oncology

UR  - http://eprints.whiterose.ac.uk/131249/

PY  - 2017/05/20

AU  - Corrie P

AU  - Marshall A

AU  - Lorigan P

AU  - Gore ME

AU  - Tahir S

AU  - Faust G

AU  - Kelly CG

AU  - Marples M

AU  - Danson S

AU  - Marshall E

AU  - Houston S et al

ED  - 

DO  - DOI: 10.1200/jco.2017.35.15_suppl.9501

PB  - American Society of Clinical Oncology (ASCO)

VL  - 35

IS  - 15_suppl

SP  - 9501

EP  - 9501

Y2  - 2024/09/19

ER  -